YU50402A - Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze - Google Patents

Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze

Info

Publication number
YU50402A
YU50402A YU50402A YUP50402A YU50402A YU 50402 A YU50402 A YU 50402A YU 50402 A YU50402 A YU 50402A YU P50402 A YUP50402 A YU P50402A YU 50402 A YU50402 A YU 50402A
Authority
YU
Yugoslavia
Prior art keywords
substituted lower
compounds
substituted
nr9r10
cyano
Prior art date
Application number
YU50402A
Other languages
English (en)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Vara Prasad Venkata N. Josyula
Dennis Joseph Mcnamara
Peter Laurence Toogood
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU50402A publication Critical patent/YU50402A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Opisana su jedinjenja formule (I), gde su R2, R7, R13, R14 i R15, nezavisno, vodonik ili (ne)supstituisani nizi alkil, (ne)supstituisani nizi alkenil, (ne)supstituisani nizi alkil, ili (ne)supstituisani -(CH2)nR12; R5 je halogen, cijano, nitro, -R9, -NR9R10 ili -OR9; R6 je halogen, cijano, nitro, -R9, -NR9R10, -OR9, -CO2R9, -COR9, -CONR9R10, -NR9COR10, (ne)supstituisani nizi alkenil, ili (ne)supstituisani nizi alkinil; R8 je -CO2R13, -COR13, -CONR13R14, -CSNR13R14, -C(NR13)NR14R15, -SO3R13, -SO2R13, -SO3NR13R14, -PO3R13R14, -POR13R14, -PO(NR13R14)2; R9 i R10 su nezavisno vodonik ili (ne)supstituisani nizi alkil; R11 je heteroaril ili heterociklil grupa; R12 je cikloalkil, heterociklil, aril, ili heteroaril grupa; n je 0, 1, 2 ili 3. Ova jedinjenja i njihovi farmaceutski preparati su korisna za tretiranje celijskih proliferativnih poremecaja, kao sto su kancer i restenoza. Ova jedinjenja su snazni inhibitori cdk i kinaza posredovanih faktorom rasta.
YU50402A 2000-01-25 2001-01-23 Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze YU50402A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
YU50402A true YU50402A (sh) 2005-11-28

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
YU50402A YU50402A (sh) 2000-01-25 2001-01-23 Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze

Country Status (34)

Country Link
EP (1) EP1254137A1 (sh)
JP (1) JP4047010B2 (sh)
KR (1) KR20020065939A (sh)
CN (1) CN1395578A (sh)
AP (1) AP2002002586A0 (sh)
AR (1) AR030044A1 (sh)
AU (1) AU2542501A (sh)
BG (1) BG106850A (sh)
BR (1) BR0107751A (sh)
CA (1) CA2397961C (sh)
CO (1) CO5261549A1 (sh)
CR (1) CR6706A (sh)
CZ (1) CZ20022475A3 (sh)
DZ (1) DZ3266A1 (sh)
EA (1) EA200200643A1 (sh)
EE (1) EE200200405A (sh)
GT (1) GT200100016A (sh)
HN (1) HN2001000013A (sh)
HU (1) HUP0204141A3 (sh)
IL (1) IL150545A0 (sh)
IS (1) IS6443A (sh)
MA (1) MA26868A1 (sh)
MX (1) MXPA02007221A (sh)
NO (1) NO20023527L (sh)
OA (1) OA12161A (sh)
PA (1) PA8510701A1 (sh)
PE (1) PE20011066A1 (sh)
PL (1) PL356802A1 (sh)
SK (1) SK10632002A3 (sh)
SV (1) SV2002000294A (sh)
TN (1) TNSN01014A1 (sh)
WO (1) WO2001055147A1 (sh)
YU (1) YU50402A (sh)
ZA (1) ZA200205879B (sh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA03003612A (es) 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
BR0309053A (pt) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CN101014600A (zh) * 2004-09-21 2007-08-08 霍夫曼-拉罗奇有限公司 用作蛋白激酶抑制剂的6－(2－烷基－苯基)－吡啶并[2,3－d]嘧啶类
AR053450A1 (es) 2005-03-25 2007-05-09 Glaxo Group Ltd Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
CN101495475A (zh) 2005-03-25 2009-07-29 葛兰素集团有限公司 制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
KR100962723B1 (ko) * 2005-07-21 2010-06-09 에프. 호프만-라 로슈 아게 단백질 티로신 포스파타제1ｂ 억제제로서의피리도[2,3-ｄ]피리미딘-2,4-다이아민 화합물
ES2351939T3 (es) 2005-08-09 2011-02-14 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas.
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
MX2011005720A (es) * 2008-12-01 2011-06-17 Merck Patent Gmbh Pirido [4,3-d] pirimidinas 2,5-diamino sustituidas como inhibidores de autotaxina contra cancer.
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
WO2014151682A1 (en) * 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20012444B (en) * 1994-11-14 2001-05-25 Warner Lambert Company Us 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
ES2310039T3 (es) * 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.

Also Published As

Publication number Publication date
PL356802A1 (en) 2004-07-12
IS6443A (is) 2002-06-25
WO2001055147A1 (en) 2001-08-02
CA2397961A1 (en) 2001-08-02
TNSN01014A1 (fr) 2005-11-10
CO5261549A1 (es) 2003-03-31
DZ3266A1 (fr) 2001-08-02
EE200200405A (et) 2003-12-15
ZA200205879B (en) 2003-09-29
MXPA02007221A (es) 2002-11-29
KR20020065939A (ko) 2002-08-14
PE20011066A1 (es) 2001-10-22
IL150545A0 (en) 2003-02-12
AP2002002586A0 (en) 2002-09-30
HUP0204141A3 (en) 2005-03-29
HUP0204141A2 (hu) 2003-04-28
GT200100016A (es) 2001-10-19
MA26868A1 (fr) 2004-12-20
JP4047010B2 (ja) 2008-02-13
AU2542501A (en) 2001-08-07
CR6706A (es) 2005-04-04
SV2002000294A (es) 2002-07-16
OA12161A (en) 2006-05-08
BR0107751A (pt) 2002-11-12
PA8510701A1 (es) 2002-12-11
EP1254137A1 (en) 2002-11-06
CN1395578A (zh) 2003-02-05
NO20023527L (no) 2002-09-10
BG106850A (bg) 2003-02-28
NO20023527D0 (no) 2002-07-24
EA200200643A1 (ru) 2002-12-26
SK10632002A3 (sk) 2003-06-03
AR030044A1 (es) 2003-08-13
CZ20022475A3 (cs) 2003-03-12
JP2003523357A (ja) 2003-08-05
CA2397961C (en) 2008-08-26
HN2001000013A (es) 2001-06-18

Similar Documents

Publication Publication Date Title
YU50402A (sh) Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze
BG106594A (en) Pteridinones as kinase inhibitors
AP2000001964A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
CA2997039C (en) 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof
RU2005127052A (ru) Соединения тиенопиримидина и их применение
CL2008001230A1 (es) Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
NZ627709A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
BG107161A (en) 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
ZA200206191B (en) Pyrimidine compounds.
BR112015002152B1 (pt) Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
AR006906A1 (es) Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
UY27198A1 (es) Nuevos compuestos antiinflamatorios de bencimidazol
HUP0300798A2 (hu) Szubsztituált triazolopirimidin-származékok és alkalmazásuk rákellenes hatóanyagként és ezeket tartalmazó gyógyszerkészítmények
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
EP1233950A4 (en) 3,4-DIHYDRO (1H) CHINAZOLIN 2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
MXPA03004023A (es) Compuestos quimicos.
DK0888356T3 (da) Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere
AR027035A1 (es) Pirroles sustituidos
TH53887A (th) ไพริโด (2,3-d) , ไพริมิดีน-2.7- ไดเอมีนที่เป็นสารยับยั้งคิเนส